IFF revises sales guidance
This article was originally published in The Rose Sheet
Executive Summary
International Flavors & Fragrances expects second quarter earnings per share will be in line with previous guidance, despite lower than anticipated sales in the quarter, the company states. Flavors and fragrance house anticipates reported dollar sales to increase 2%-3% in the period rather than 5% as previously predicted. Sales benefited from the strengthening of various currencies in relation to the U.S. dollar, but had exchange rates remained constant between 2003 and 2002, sales for Q2 would have declined approximately 5%-6%. Sales performance reflects "marked slow-down in customer order activity" in the quarter, particularly in Europe and North America, IFF adds...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.